arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

INTENSITY THERAPEUTICS, INC.

INTS
$4.31 ▲ +0.06 (+1.41%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

INTENSITY THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $10.9M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -20.0%
FCF / Share $-0.72
Trailing P/E
Price / Book 1.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-2.43M
↑ +27.3%
FCF / Share Free cash flow per share
$-0.72
↑ +78.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters